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Background: HIV-1 p17 binds heparin and heparan sulfate proteoglycans of the cell surface.
Results:Heparin/p17 interaction occurs throughheparin sulfate groups and a linear basicmotif of p17N terminus, also involved
in p17/CXCR1 interaction.
Conclusion: Targeting the basic motif inhibits p17-receptors interaction and consequent biological activities.
Significance: Heparin-like molecules represent template for the development of new treatments of p17-dependent/AIDS-
associated pathologies.
Once released by HIV cells, p17 binds heparan sulfate pro-
teoglycans (HSPGs) and CXCR1 on leukocytes causing their
dysfunction. By exploiting an approach integrating computa-
tional modeling, site-directed mutagenesis of p17, chemical
desulfation of heparin, and surface plasmon resonance,we char-
acterized the interaction of p17with heparin, aHSPG structural
analog, and CXCR1. p17 binds to heparin with an affinity (Kd
190 nM) that is similar to those of other heparin-binding viral
proteins. Two stretches of basic amino acids (basic motifs) are
present in p17 N and C termini. Neutralization (Arg3Ala sub-
stitution) of the N-terminal, but not of the C-terminal basic
motif, causes the loss of p17 heparin-binding capacity. The
N-terminal heparin-binding motif of p17 partially overlaps the
CXCR1-binding domain. Accordingly, its neutralization pre-
vents also p17 binding to the chemochine receptor. Competi-
tion experiments demonstrated that free heparin and heparan
sulfate (HS), but not selectively 2-O-, 6-O-, and N-O desulfated
heparins, prevent p17 binding to substrate-immobilized hepa-
rin, indicating that the sulfate groups of the glycosaminoglycan
mediate p17 interaction. Evaluation of the p17 antagonist activ-
ity of a panel of biotechnological heparins derived by chemical
sulfation of the Escherichia coliK5 polysaccharide revealed that
the highlyN,O-sulfatedderivative prevents the binding of p17 to
bothheparin andCXCR1, thus inhibiting p17-driven chemotac-
tic migration of human monocytes with an efficiency that is
higher than those of heparin andHS.Here, we characterized at a
molecular level the interaction of p17with its cellular receptors,
laying the basis for the development of heparin-mimicking p17
antagonists.
The matrix protein p17 plays important roles in HIV-1 life
cycle (1) regulating both early and late stages of viral replication
such as P55GAG transport to the membrane (2) and envelope
glycoproteins incorporation into nascent virions (3). p17 is also
released by HIV-infected cells, being detectable in plasma (4),
brain (5), and lymph nodes (6) even in patients successfully
treated with highly active antiretroviral therapy (6). Extracellu-
lar p17 deregulates the functions of many immune cells
involved in AIDS pathogenesis (7): it reducesMIP-1 secretion
in activated monocytes (8), induces activated T cell prolifera-
tion enhancingHIV replication (9), increases IFN- andTNF-
production decreasing the ability of IL-4 to down-regulate the
secretion of such cytokines in activated peripheral bloodmono-
nuclear and natural killer cells (7, 10). Three distinct cellular
receptors for p17 have been identified: the chemokine recep-
tors CXCR1 and CXCR2, which mediate p17-driven monocyte
migration (11) and endothelial cells proangiogenic activation
(12), respectively, and heparan sulfate proteoglycans (HSPGs),2
tentatively associated to p17-driven cytokine up-regulation in
CD4 lymphocytes (13, 14).
HSPGs typically consist of a core protein and of glycosamin-
oglycan (GAG) chainsmade up of unbranched anionic polysac-
charides resembling heparin and composed of repeating disac-
charides units formed by sulfated uronic acid and hexosamine
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residues (15). They are expressed at densities ranging between
105 and 106/cell on the surface of almost all eukaryotic cells
where they play co-receptor function for a wide array of hepa-
rin-binding cytokines. HSPGs, as well as their structural analog
heparin, can be also found in a free form in the extracellular
environment (16) where they act as antagonists, sequestering
heparin-binding cytokines and hampering their cell surface
interactions. The wide distribution and strong interactive
capacity of HSPGs made them attractive adhesion molecules
for viruses during their evolution. In effect, virus attachment to
host cell is often mediated by their interaction with cellular
HSPGs (17). Conversely, free heparin-like molecules can
inhibit viral infection. Accordingly, a long list of heparin-like
polyanions have been so far developed as effective antiviral
compounds in vitro (18). However, the therapeutical exploita-
tion of these compounds as antiviral drugs is limited by the fact
that HSPGs act also as receptors for a wide array of cytokines
involved in critical biological events such as cell growth and
migration and the maintenance of normal tissue structure and
function (16). These considerations call for the development of
specific heparin-like compounds able to discriminate between
viral and eukaryotic proteins. This, in turn, calls for the fine
characterization of the interaction of each viral protein with
heparin/HSPGs.
In general, the binding of heparin/HSPGs to viral proteins
occurs through negatively charged sulfate groups of the GAG
and clusters of positively charged amino acids of the protein
also termed “basic motifs” (18). Both the sulfation degree and
disposition of sulfate groups along the GAG chain are impor-
tant in determining the interactive capacity (18). In heparin-
binding proteins, unique or multiple basic motifs can be found
composed of linear stretches of basic amino acids as in HIV-1
Tat or of conformational cluster of scattered basic amino acids
that crowd together in the properly folded protein as in fibro-
blast growth factor 2 (FGF2) (19).
HIV-infected cells secrete three proteins (Tat, gp120, and
p17) that, amazingly, share heparin-binding capacity. Tat/hep-
arin interaction occurs with a dissociation constant (Kd) equal
to 30–60 nM (20, 21) and is mainly mediated by a linear basic
motif 49RKKRRQRRR57 located at the C terminus of the pro-
tein (22), with a minor contribution of three other basic amino
acids (Lys12, Lys41, and Arg78) spatially enclosed in the native
protein (23). At least some 2-O-, 6-O-, and N-positions along
the GAG chain need to be sulfated to allow Tat binding (24),
and a hexasaccharide is theminimal heparin length that retains
Tat-binding capacity (25).
gp120 binds heparin with aKd equal to 200–600 nM (26, 27).
Distinct basic domain are present in the protein, among which
the C-terminal “variable loop 3” (18, 28) is implicated in gp120
binding to cell surface HSPGs and consequent HIV infection
(26). On the heparin chain, O-, but not N-sulfated groups are
necessary for the binding to gp120 (29–31). An octa/decasac-
charide is the minimal heparin size that retains gp120-binding
capacity (32).
At variance with Tat and gp120, no data are available about
the molecular bases of p17/heparin interaction. The structure
of monomeric (33) and trimeric (34) p17 were determined,
demonstrating highly similar three-dimensional structures
(35). p17 folds into a compact core domain consisting of five
-helices and three stranded -sheets. -Helices 1–4 form a
compact globular domain, whereas the C-terminal helix 5 is
partially unfolded, projecting away from the protein, readily
accessible for interactions such as that between p17 to P55GAG
capsid domains. p17 possesses two basic motifs that maymedi-
ate its binding to heparin: in the monomer as well as in the
trimer, they are both exposed on the protein surface, one in the
N-terminal globular domain of the protein spanning residues
25–34, the other in its partially unfolded C-terminal tail span-
ning residues 109–115 (see Fig. 1, A and B). Both of the motifs
are not involved in mediating oligomerization of p17, remain-
ing exposed onto the protein surface also when it takes its tri-
meric form (see also Fig. 1B) (34, 35). Here, by integrating com-
putational modeling, site directed mutagenesis of p17,
chemical desulfation of heparin, and real time biomolecular
interaction analysis by surface plasmon resonance (SPR), we
characterized the interaction of p17 to heparin at a molecular
level.
MATERIALS ANDMETHODS
Molecular Modeling—The structures of monomeric p17
were obtained from the Protein Data Bank (PDB) code 1TAM.
The structural models of the heparin di-, tetra-, and hexasac-
charides were built using the PyMOL program based on their
NMR solution structure (PDB code 1HPN). The results for the
1C4 conformers were here reported, but similar results were
obtained with the 2SO conformers (data not shown). Docking
of oligosaccharides to p17 was performed with Autodock (ver-
sion 4.0) (36, 37), which allows flexibility in the heparin struc-
ture but uses a rigid body protein approximation to speed up
the calculation. Two-step docking simulation was employed.
First, a blind docking protocol was used on the monomeric
form to predict the bound conformation with no a priori
knowledge of binding site locations on the molecules (38, 39).
To this aim, a grid box encompassing the entire p17 structure
was generated to take all possible heparin binding sites into
account. In a second set of experiments, a smaller grid, focused
on the binding region identified in the blind docking was used
to predict the binding mode of the heparin oligosaccharides
and to optimize the ligand-protein interactions in the potential
heparin binding site. In particular, affinitymaps for all the atom
types present, as well as an electrostatic map, were computed
with a grid spacing of 0.375 Å. The search was carried out with
the LamarckianGenetic Algorithm, the number of generations,
energy evaluations, and docking runs were set to 500,000,
2,500,000, and 100, respectively. Eventually, the evaluationwith
the lowest binding energy was used to analyze ligand pose and
the interaction models of heparin oligosaccharides with the
monomeric form of p17.
We also performed docking simulations of heparin with the
trimeric p17 complex. Relevant to this, the only available three-
dimensional structure of trimeric p17 was generated on a pro-
tein containing the N-terminal basic motif GKKQYKLKHI
(Swiss Prot code P12497, PDB code 1HIW) (34), thus different
from the p17 here used for experiments in vitro and for molec-
ular modeling with the monomer containing the N-terminal
basic motif GKKYKLKHI (Swiss Prot code P04585, PDB code
HIV-1 Protein p17 and Heparin
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1TAM). Thus, a homologymodeling approachwas used to gen-
erate the three-dimensional structure of the trimeric form of
the p17 studied experimentally. Briefly, the PDB code 1HIW
was used as a template; sequence alignment of template and
target (93%) was given as input to Modeler program (40) to
build three-dimensional structures (Fig. 1F). The three-dimen-
sional model was subjected to energy minimization using the
Gromacs program (41) and evaluated using PROCHECK (42).
Themodel obtained was submitted to docking simulations and
grids focused on three N-terminal binding sites were used to
predict the binding mode of heparin oligosaccharide in the rel-
ative positions.
All calculations were performed on a Linux Cluster of 32
nodes, each SuperMicro equippedwith twoprocessors: the 2.50
GHz INTEL(R)Quad-core and the 16GBXeon(R), for 256 total
processors and 512 GB of RAM. Figures were realized with the
PyMOL Molecular Graphics System (DeLano Scientific, San
Carlos, CA).
Recombinant Proteins—The coding sequence of HIV-1
matrix protein p17 clade B isolate BH10 (amino acids 1–132)
was amplified by PCR with specific primers, allowing the clon-
ing of the p17 sequence into the BamH1 site of the expression
vector pGEX-2T (GE Healthcare). p17 N-terminal Lys3Ala
mutant, obtained by the substitution of lysines of the N-termi-
nal basic motif with alanine, and the p17 C-terminal K3A
mutant, obtained by the same mutations in the C-terminal
basic motif, were cloned into the BamH1 site of the pGEX-2T
vector using QuikChange site-directed mutagenesis kit (Strat-
agene, La Jolla, CA). p1736, obtained by the deletion of the
C-terminal sequence 97–132, was prepared as described (43).
See Fig. 3A for a schematic representation of the p17 mutants.
p17 proteins and the GST motif alone were purified as
described (43). Human recombinant FGF2 was expressed in
Escherichia coli and purified as described (44). Synthetic 86-
amino acid HIV-1 Tat was from Xeptagen (Venezia, Italy). The
absence of endotoxin contamination (0.25 endotoxin units/
ml) in protein preparations was assessed by Limulus amoebo-
cyte assay (Associates of Cape Cod, Inc., East Falmouth, MA).
Heat denaturation of proteins was obtained by incubation at
95 °C for 5 min.
Glycosaminoglycans—Type I HS was from Opocrin (Corlo,
Italy). Conventional heparin (13.6 kDa) was obtained from a
commercial batch preparation of unfractionated sodium hepa-
rin from beef mucosa (Laboratori Derivati Organici S.p.A.,
Milan, Italy) purified from contaminants (up to 95%) according
to described methodologies. Selectively desulfated heparins
were a gift of Dr. B. Casu (Ronzoni Institute) (45). Size-defined
heparin-derived oligosaccharides were from Iduron (Man-
chester, UK). The capsular E. coli K5 polysaccharide has the
same structure as the heparin precursor N-acetyl heparosan
(46). K5 derivatives were obtained byN-deacetylation/N-sulfa-
tion and/orO-sulfation of a single batch ofK5polysaccharide as
described (47). For further details on the GAGs used in this
study, see Table 1.
SPR Binding Assay—SPR measurements were performed on
a BIAcore X instrument (GE Healthcare). For the study of p17/
heparin interaction, biotinylated heparin was immobilized
onto a SA sensorchip containing preimmobilized streptavidin,
allowing the immobilization of 159 resonance units (RU), equal
to 11.7 fmol/mm2 of heparin. A sensorchip precoated with
streptavidin alonewas used to evaluate nonspecific binding and
for blank subtraction (21). Increasing concentrations of p17 or
of its mutants in 10 mM HEPES, pH 7.4 containing 150 mM
NaCl, 3 mM EDTA, and 0.005% surfactant P20 (HBS-EP) were
injected over the heparin or streptavidin surfaces for 4 min and
then washed until dissociation. After each run, the sensorchip
was regenerated by injection of 2.0 M NaCl in HBS-EP.
For the study of p17/CXCR1 interaction, anti-GST antibod-
ies were immobilized onto a CM5 sensorchip using standard
amine-coupling chemistry. Then, recombinant human CXCR1
with a C-terminal GST tag (10 g/ml in 50 mMHEPES, pH 7.0,
containing 0.01% cholesteryl hemisuccinate Tris salt, 0.1%
CHAPS, and 0.33 mM synthetic phospholipid blend (dioleoyl)
DOPC:DOPS (7:3 (w/w), Avanti polar lipids) was injected over
the anti-GST surface, allowing the immobilization of 1,600 RU,
equal to 25 fmol/mm2 of the receptor. A sensor chip coated
with anti-GST antibodies was used as a negative control and for
blank subtraction (11). Increasing concentrations of p17 or of
its mutants in HBS-EP were injected over the CXCR1-coated
surfaces for 15 s and then washed until dissociation.
For competition experiments, p17 (500 nM) and increasing
concentrations of the different GAGs were preincubated for 10
min at 25 °C and then injected over the heparin or CXCR1
surfaces. Alternatively, p17 was injected over the sensor chips
TABLE 1
Structural features of the GAGs utilized in the present study
MWa SO3/COO Glc-NSO3 Glc-6SO3 IdoA-2SO3 GlcA-OSO3b GlcA2,3SO3
Unsulfated
GlcA
% % % % %
Heparin/HS
Unmodified 13,600 2.14 78 77 59
2-O-Desulfated 9,600 1.60 78 80 5
6-O-Desulfated 10,300 1.50 100 0 50
N-Desulfated/N-acetylated 12,300 1.50 10 80 60
Heparan sulfate 18,000 1.17 42 44 31
K5 polysaccharides
Unsulfated 30,000 0.00 0 0 0 0 100
K5NS 15,000 1.00 100 0 0 0 100
K5OSL 14,000 1.41 0 90 10 0 90
K5OSH 11,000 3.77 0 100 0 100 0
K5NOSL 13,000 1.70 100 90 10 0 90
K5NOSH 15,000 3.84 100 100 30 70 0
aMW, molecular weight.
b GlcA2SO3 or GlcA3SO3.
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and allowed to reach an equilibrium binding. Then, increasing
concentrations of the various GAGs were injected, and p17
detachment from the surfaces was evaluated. Similar results
were obtained in the two experimental approaches (data not
shown).
Kinetic parameters were calculated from the sensorgram
overlays by using the nonlinear fitting single site model soft-
ware package BIAevaluation (version 3.2). Only sensorgrams
whose fitting gave 2 values close to 10 were used (48). Also,Kd
was calculated by being fitted with the proper form of
Scatchard’s equation for the plot of the bound RU at equilib-
rium versus the ligand concentration in solution. All fittings
were performed by the software Solar, a least-square mini-
mization procedure based on the Levemburg-Marquardt
algorithm.
Isolation of Human Monocytes and Chemotaxis Assay—
Blood was collected from healthy donors who gave informed
consent according to the Helsinki Declaration. All procedures
were done under sterile conditions using reagents prepared in
endotoxin-free water for clinical use. Human monocytes were
isolated from whole blood by Ficoll  Percoll gradient sedi-
mentation (49) and resuspended in migration buffer (phos-
phate-buffered saline, pH 7.2, containing 1 mM CaCl2, 1 mM
MgCl2, and 10% fetal calf serum). Monocyte migration was
assessed in 3-m pore-size Transwells (BD Biosciences). Ali-
quots (100 l) of cells (2  106/ml) in migration buffer were
added to the top well in the absence or in the presence of hep-
arin, HS, or K5NOSH (at 1 and 10 g/ml). Aliquots (600 l) of
mediumwith or without p17 (59 nM) orN-formyl-L-methionyl-
L-leucyl-L-phenylalanine (fMLP, 10 nM) were added to the bot-
tomwell. Chemotaxis was performed for 90min at 37 °C. Then,
the filters were removed. After fixation with 1.5% paraformal-
dehyde, migrated cells were counted in five high-power fields
by light microscopy at 10magnification.
RESULTS
Molecular Docking Studies—To identify the heparin-binding
site in the monomeric p17, we performed blind docking simu-
lations in order to predict the binding mode and obtain an esti-
mate of the total interaction energy of the complexes. For all
three heparin oligosaccharides used (di-, tetra-, and hexasac-
charide), the lowest energy docking was predicted to be located
in the N-terminal basic motif of p17 instead of the C-terminal
one, although both these motifs are exposed onto the protein
surface both in its monomeric and trimeric form. Comparable
results were obtained by using either the 1C4 or 2SO conform-
ers of the three heparin oligosaccharides (data not shown).
Thus, local docking simulations were carried out to predict the
binding mode of the heparin oligosaccharide and to optimize
the ligand-protein interactions in the potential heparin binding
site identified. As shown in Fig. 1, C–F, and Table 2, p17 is
predicted to interact with heparin by an extensive hydrogen-
bonding network occurring mainly between the lysines of the
N-terminal basic motif of p17 and the negatively charged sul-
fate groups of heparin. In particular, the heparin disaccharide
may form five hydrogen bonds with residues Lys-27, Lys-28,
and Lys-30 of p17; the heparin tetrasaccharide may form 10
hydrogen bonds with residues Lys-27, Lys-28, Lys-30, and
Lys-32 localized at the beginning of the second -helix; the
heparin hexasaccharidemay instead bind p17with 12 hydrogen
bonds involving the same residues of the tetrasaccharide plus
residue Arg-39 located in the middle of the -helix. Thus, hep-
arin di- and tetrasaccharide may bind to basic amino acids that
are contiguous in the basic motif of p17, whereas the heparin
hexasaccharide is predicted to bind another residue (Arg-39)
that in the folded structure is close to the linear basic motif but
in the sequence is distant.
We also evaluated the binding mode of heparin oilgosaccha-
rides with p17 in its trimeric form. As already described under
“Materials and Methods,” the three-dimensional structure of
the trimeric form of the p17 used experimentally (containing
the N-terminal basic motif GKKYKLKHI) has not been
resolved, prompting to achieve a three-dimensional homology
model of its trimeric form by using as a template the available
x-ray structure of a p17 trimer containing a N-terminal basic
motif GKKQYKLKHI (Swiss Prot code P12497, PDB code
1HIW). As inferred by previous papers (34, 35), the putative
heparin-binding N-terminal basic motif GKKYKLKHI remains
exposed onto the p17 surface also in the trimeric form (Fig. 1B).
Molecular docking of the hexasaccharide against modeled
complex of p17 was performed on three N-terminal sites. The
conformations and interactions of docked hexasaccharides in
the binding sites of p17 are shown in Fig. 1F. Also, in the trim-
eric complex of p17, the residues involved in the hydrogen
bonds network are the basic residues of the N-terminal motif,
Arg-39, and sulfate groups of heparin. The structural analysis of
the trimeric form complexed with the ligands suggests a hex-
asaccharide binding pocket of 26.5 Å long. The distance
between the heparin binding pockets of chainA and B, between
chain B andC, and between chain C andA are 26, 23.1, and 17.5
Å, respectively (Fig. 1F). These structural considerations sug-
gest that, to interact with more than one binding site, the hep-
arin chain should be composed of at least 18 saccharide units.
Biochemical Characterization of p17/Heparin Interaction—
SPR was exploited to evaluate the capacity of p17 to bind sens-
orchip-immobilized heparin, a model that mimics the binding
of proteins to cell surface-associated HSPGs (20). p17 interacts
with immobilized heparin but not with streptavidin (Fig. 2A).
When increasing concentrations of p17 were injected onto the
heparin surface, the sensorgram overlay shown in Fig. 2B was
obtained that allowed the calculation of association (kon) and
dissociation (koff) rates and of Kd (as koff/kon ratio, Table 3).
Also, equilibrium binding data were used to generate the satu-
ration curve and Scatchard plot regression shown in Fig. 2C and
used to calculate a Kd value independent from kinetic parame-
ters (Table 3). In conclusion, p17 binds immobilized heparin
with aKd (136–190nM) that is similar to those of other heparin-
binding proteins (Table 3).
To evaluate whether a proper three-dimensional configura-
tionwas necessary to p17 to bind heparin, the protein was incu-
bated for 5min at 95 °C and immediately analyzed in SPR for its
capacity to bind to immobilized heparin. FGF2 and Tat were
used as controls because their interactions with heparin were
already demonstrated to depend on conformational and linear
basic domain and motif, respectively (50, 51). As expected,
incubation at 95 °C for 5 min causes the complete loss of FGF2
HIV-1 Protein p17 and Heparin
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heparin-binding capacity (Table 3). At variance, it does not
hamper the heparin-binding capacity of both Tat and p17,
inducing only a decrease of the affinity of these interactions
(Table 3). Important to note, p17 loses its capacity to bind to
CXCR1when used immediately after its heating (Table 3), indi-
cating its effective unfolding. In conclusion, p17 interaction
FIGURE 1. Shown is the localizationof basicmotifs inmonomeric (A) and trimeric (B) p17. Theproteins are shownasConnolly surface. The chains are colored ingreen,
yellow, andmagenta. The N-terminal and C-terminal basic motifs are labeled in blue and cyan, respectively. Predicted bindingmodes between the N-terminal basic
motifofp17andheparindi- (C), tetra- (D), andhexasaccharide(E)areshown.Shownarestickoligosaccharides (green)andthesidechainsofp17that interactwiththem
(cyan). Protein is shownasa ribbon, andthehydrogenbondsare representedbymagentadotted lines.F, predictionof thebindingmodeof theheparinhexasaccharide
at the three N-terminal sites. Themodeled trimeric form of p17 is shown as Connolly surface, A chain, B chain, and C chain are colored in cyan,magenta, and yellow,
respectively. The N-terminal basicmotifs of each chain are colored in blue. The ligands are shown in the Corey, Pauling, and Koltun space filling-model.
TABLE 2
Docking results obtained with Autodock for heparin oligosaccharides binding to the N-terminal basic motif of monomeric p17
Oligosaccharide probe
molecules
Groups of heparin involved in hydrogen bond Total interaction energy
of the complex2-O-Sulfate N-Sulfate 6-O-Sulfate Carboxyl 3-O-Sulfate
kcal/mol
Disaccharide 1C4 Lys27 Lys28, Lys30 Lys27 13.57
No. of hydrogen bonds 1 3 1
Tetrasaccharide 1C4 Lys28, Lys32 Lys30 Lys26 Lys27 Lys28 19.06
No. of hydrogen bonds 3 2 2 2 1
Hexasaccharide 1C4 Lys27, Arg39 Lys27 Lys28, Lys30 Lys32 Lys32 22.28
No. of hydrogen bonds 4 1 4 2 1
HIV-1 Protein p17 and Heparin
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with heparin depends mainly on linear basic motifs rather than
on conformational motifs.
Although p17 possess two distinct stretches of basic amino
acids (25GKKKYKLKHI34 and 109NKSKKKA115) that may act
as heparin-binding motifs, the blind docking simulations indi-
cated that only the N-terminal one mediates p17 binding to
heparin (see above). Thus, two p17 mutants were produced in
which the lysines within theN- or C-terminal basicmotifs were
neutralized by substitution with alanine (p17 N-terminal
Lys3Ala and p17 C-terminal Lys3Ala, respectively). Also,
taking advantage of the unfolded nature of the C terminus of
p17, we produced a deletion mutant (p1736) lacking the last
36-amino acid portion containing the C-terminal basic motif
(Fig. 3A). As shown in Fig. 3B, p17 N-terminal Lys3Ala com-
pletely loses its capacity to bind immobilized heparin, whereas
p17 C-terminal Lys3Ala retains its heparin-binding capacity
(Fig. 3C and Table 3). This latter result was paralleled by the
observation that also the deletion mutant p1736 retains its
capacity to bind heparin (Fig. 3D and Table 3). In conclusion,
the N-terminal but not the C-terminal basic motif of p17medi-
ates the interaction of the protein to heparin/HSPGs.
The capacity of heparin to bind to different proteins depends
on its degree of sulfation, disposition of the sulfate groups and
length of the saccharidic chain (18, 52). To identify the bio-
chemical features of heparin involved in its binding to p17, we
exploited a SPR competition assay already used to evaluate the
HSPGs antagonist capacity of various polyanionic compounds
(20). As shown in Fig. 4A, both heparin and HS displace p17
from its binding to sensorchip-immobilized heparin in a dose-
dependent manner, with the former exerting a stronger inhibi-
tion in respect to the latter (ID50 18 and 80 nM, respectively).
As HS is less sulfated than heparin (SO3/COO ratio  0.93
and 2.14, respectively, see Table 1), it can be concluded that the
degree of sulfation is important in determining the p17-binding
capacity of heparin/HS.
Next, a series of selectively desulfated heparin (Table 1) was
evaluated for their capacity to bind p17. Selective desulfation of
2-O, 6-O, and N positions abolishes the capacity of heparin to
interact with p17 (Fig. 4A), indicating that all of the sulfate
groups of heparin are important for its p17-binding capacity.
Finally, a series of size-defined heparin oligosaccharideswere
evaluated for their capacity to compete with sensorchip-immo-
bilized full-length heparin for the binding to p17. As shown in
Fig. 4C, at the doses tested, all of the oligosaccharides except the
disaccharide compete with immobilized heparin for the bind-
ing to p17 with potencies that increase logarithmically with
their size. Taken together, these results indicate that the p17-
binding capacity of heparin is greatly influenced by the length of
its saccharidic chain.
Biochemical Characterization of p17-CXCR1 Interaction—In
addition to HSPGs, also CXCR1 acts as p17 receptor on leuko-
cytes (11). Interestingly, the extracellularN-terminal domain of
CXCR1 is highly negatively charged (53), and the N-terminal
basic motif 25GKKKYKLKHI34 of p17 partially overlaps with
the p17 receptor binding domain 9SGGELDRWEKIRLRPGG-
KKK28 (54). These observations prompted us to investigate
whether neutralization of the basic amino acids of theN-termi-
nal basic motif of p17 affected the interaction of the protein to
the chemokine receptor. The interaction of wild type p17 with
CXCR1 has been already characterized (11). Here, we observed
that p17 N-terminal Lys3Ala, but not p17 C-terminal
Lys3Ala, completely loses its capacity to bind to CXCR1 (Fig.
5 and Table 3), indicating that, in addition to heparin/HSPGs,
theN-terminal basicmotif of p17 is also required for its binding
to CXCR1.
Biotechnological Heparins as p17 Antagonists—K5 deriva-
tives produced by chemical sulfation of N- or O-positions are
endowed with defined sulfation patterns and with the capacity
to hamper different biological activities of both Tat and gp120
(31, 55). Here, we assessed the p17-binding and antagonist
capacity of a panel of K5 derivatives including the following:
N-sulfatedK5 (K5NS),O-sulfatedK5with low and high degrees
of sulfation (K5OSL andK5OSH) andN,O-sulfatedK5with low
FIGURE 2. SPR analysis of p17-heparin interaction. A, sensorgrams show-
ing the binding of native p17 (500 nM) to a heparin- or streptavidin-coated
sensorchip. B, blank-subtracted sensorgrams overlay showing the binding of
increasing concentrations of native p17 (1000, 500, 250, 125, 62.5, and 31.25
nM) to a heparin-coated sensorchip. Black lines represent the experimental
data. Red lines represent the fits. InA and B, the response (in RU)was recorded
as a function of time. C, saturation curve obtained using the values of RU
bound at equilibrium from injection of increasing concentrations of p17 onto
a heparin-coated sensorchip. C, inset: Scatchard plot analysis of the equilib-
rium binding data shown in C. The correlation coefficient of the linear regres-
sion was equal to0.96.
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and high degrees of sulfation (K5NOSL andK5NOSH) (Tab. 1).
As shown in Fig. 6A, K5NOSH inhibits the binding of p17 to
immobilized heparin with a potency that is higher than that of
unmodified heparin (ID50 2.5 and 18nM, respectively). K5NS,
K5OSL, K5NOSL and K5OSH are less effective (ID50  30.0,
60.0, 56.0 and 70.0 nM respectively). If compared with the other
sulfated derivatives, unsulfated K5 exerts a very limited inhibi-
tion (less than 40%)when assayed at 100 nM, suggesting that the
contribution of the backbone sugar in p17 interaction is limited
in respect to the contribution of sulfate groups. Except for
K5NS and K5OSH (discussed below), a clear correlation exists
between the SO3/COO ratio and the p17-heparin inhibitory
capacity of the GAGs tested (Fig. 6A, inset), further sustaining
the importance of the sulfation degree in the p17-binding
capacity of heparin/HSPGs.
We then evaluated the ability of the K5 derivatives to inhibit
the interaction of p17 to surface-immobilized CXCR1. Prelim-
inary assays demonstrated that the GAGs tested do not bind
directly to sensorchip-immobilized CXCR1 (data not shown).
As shown in Fig. 6B, K5NOSH inhibits p17-CXCR1 interaction
with the highest efficiency (ID50  2.6 nM) followed by K5NS,
K5OSL, K5NOSL, and K5OSH (ID50 48.0, 57.0, and 90.0 nM,
respectively). Instead, K5OSL, and unsulfated K5 were ineffec-
tive. Heparin and HS are weak inhibitors of the p17-CXCR1
interaction (ID50 70.0 and 250.0 nM, respectively). There is no
statistical correlation between the SO3/COO ratio and the
TABLE 3
Binding parameters of the interaction of p17 and p17mutants to heparin and CXCR1
kon and koff are reported. Kd value was either derived from the koff/kon ratio and by Scatchard plot analysis of the equilibrium binding data. The results shown are
representative of other two that gave similar results. For a comparison, the binding parameters of native or heat-denatured FGF2 and Tat are reported. n.d., not
determinable; n.c., not calculated.
kon koff Kd(kon/koff) Kd at equilibrium
1/Ms 1/s M M
Control proteins-heparin
Native FGF2 8.14 103 3.20 104 3.9 108 n.c.
Heat-denatured FGF2 n.d. n.d. n.d. n.d.
Native Tat 4.58 104 2.07 103 4.5 108 n.c.
Heat-denatured Tat 5.89 103 1.37 103 2.3 107 n.c.
p17-heparin
Native p17 3.39 105 0.0643 1.9 107 1.36 107
Heat-denatured p17 4.32 105 0.217 5.03 107 4.23 107
p17 N-terminal Lys3Ala n.d. n.d. n.d. n.d.
p17 C-terminal Lys3Ala 8.14 105 0.247 3.05 107 1.02 106
p1736 1.70 104 1.72 103 1.01 107 3.13 107
p17-CXCR1
Native p17 5.89 104 0.102 1.73 106 n.c.
Heat-denatured p17 n.d. n.d. n.d. n.d.
p17 N-terminal Lys3Ala n.d. n.d. n.d. n.d.
p17 C-terminal Lys3Ala 3.22 105 0.128 3.97 107 n.c.
FIGURE3.SPRanalysis of the interactionofp17mutantswithheparin.A, schematic representationof thep17mutants used in thepresentwork. TheN- and
C-terminal basic motifs of p17 (white boxes) were deleted or neutralized (black boxes) by substituting positively charged lysine with alanine (underlined).
Blank-subtracted sensorgrams showing the binding of p17 N-terminal (N-ter) Lys3Ala (500 nM) (B), p17 C-terminal (C-ter) Lys3Ala (500, 250, 125, 62.5, and
31.25 nM) (C) and p1736 (950, 900, 800, 500, 250, and 100 nM) (D) to a heparin-coated sensorchip. The response (in RU) was recorded as a function of time.
HIV-1 Protein p17 and Heparin
1156 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 288•NUMBER 2•JANUARY 11, 2013
 at BIBL D
ELLA FAC DI M
ED, on January 14, 2013
w
w
w
.jbc.org
D
ow
nloaded from
 
p17-CXCR1 inhibitory capacity of the various GAGs tested
(data not shown).
Both HSPGs and CXCR1 have been implicated in p17-in-
duced activation of leukocytes (11, 14). Because K5NOSH
inhibits the interaction of p17 with both heparin and CXCR1,
we evaluated its capacity to prevent p17-dependent migration
of monocytes. Heparin and HS, which efficiently inhibit p17
binding to heparin but not to CXCR1, were used as controls. As
shown in Fig. 7, K5NOSH efficiently inhibits monocyte migra-
tion to p17 both at 1 and 10 g/ml, whereas heparin shows a
significant reduced inhibitory potency, as it is active only at 10
g/ml. HS was ineffective, however, at both the concentrations
tested.
To exclude that K5NOSH aspecifically inhibit cell migration,
the assay was repeated with fMLP instead of p17. As shown in
Fig. 7, K5NOSH does not affect fMLP-driven migration of
monocytes when tested at 1 g/ml, exerting a 50% inhibition
only at doses ten times higher. In addition, K5NOSH does not
FIGURE 4. Effect of chemically modified heparins or size-defined oligo-
saccharides on the interactionof p17 to immobilizedheparin. Selectively
desulfated heparins (A) or size-defined heparin oligosaccharides (B) were
evaluated for their capacity to inhibit the interaction of p17 with sensorchip-
immobilized heparin. In A, the responses were plotted as percentage of the
binding of p17 measured in the absence of free GAGs. Each point is the
mean	 S.E. of three separate determinations. In B, the responses were plot-
ted as ID50 of inhibition. The experiment shown is representative of another
one that gave similar results. UMFH, unmodified heparin. B, inset, the loga-
rithm of the potency (ID50) of the various size-defined heparin oligosaccha-
rides in inhibiting the binding of p17 to immobilized heparin were plotted
against their length (monomer units). The correlation coefficient of the linear
regression was equal to0.93.
FIGURE 5. SPR analysis of the interaction of p17 mutants with CXCR1.
Blank-subtracted sensorgrams showing the binding of wild type p17 (contin-
uous line), p17 C-terminal (C-ter) Lys3Ala (dashed line), and p17 N-terminal
(N-ter) Lys3Ala (dotted line) (all at 2 M) to a CXCR1-coated sensorchip. The
response in RU was recorded as a function of time.
FIGURE 6.Effect of biotechnological heparins on the interactionof p17 to
its receptors. K5 derivatives were evaluated for their capacity to inhibit the
interaction of p17 with heparin (A) or CXCR1 (B) immobilized to a sensorchip.
The responseswere plotted as percentage of the binding of p17measured in
the absence of any free GAG. Each point is the mean	 S.E. of three separate
determinations. A, inset, the potency (ID50) of the various GAGs in inhibiting
the binding of p17 to immobilized heparin were plotted against their SO3
/
COO ratio. The correlation coefficient of the linear regression was equal to
0.96.
FIGURE 7. Effect of heparin, HS and K5NOSH on monocyte migration
inducedbyp17.Monocytes in theabsence (control, ctrl) or in thepresenceof
heparin, HS and K5NOSH (all at 1 and 10 g/ml) were added to the top well,
whereasmedium alone or containing p17 (59 nM) or fMLP (10 nM) was added
to the bottom well. Bars represent the mean 	 S.D. of three independent
experiments performed in duplicate. Statistical analysis was performedusing
GraphPad Prism software (version 5, GraphPad Software, Inc.) and one-way
analysis of varaince and Bonferroni’s post test was used to compare data.
*, p 0.01 statistically different compared with p17-stimulated cells. NT, not
treated cells.
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affect the basal monocytes migrationmeasured in the presence
of medium alone.
DISCUSSION
HIV-infected cells release Tat, gp120, and p17 proteins that,
acting in a cytokine-like manner, target uninfected leukocytes
(56, 57), neurons (58–60), and endothelial cells (20, 60, 61)
inducing various biological effects that, in turn, favor viral
spread and the onset of AIDS-associated diseases. Some of
these effects depend on the interaction of the viral proteinswith
HSPGs expressed on the surface of target cells (18, 52, 62),
making this class of receptors a promising nodal targets for the
development of “multitarget” anti-HIV drugs. This aim
requires the fine characterization of the molecular bases of the
interaction of the viral proteins with heparin/HSPGs, a study
that has been already performed for Tat and gp120, leading to
the development of heparin-like compounds endowed with
gp120 and/or Tat antagonist capacity (18, 52, 62). Differently,
the characterization of the interaction of p17 with heparin/
HSPGs has not been performed yet. Here, we report about the
biochemical features of p17 and of heparin that govern their
interaction.
p17 unfolding does not hamper its binding to heparin, caus-
ing only a 3-fold reduction of the affinity of the interaction.
Interestingly, a similar behavior has been observed also for Tat,
whose interaction with heparin depends mainly on a
49RKKRRQRRR57 linear basicmotif with additional but limited
contribution given by three other spatially enclosed basic
amino acids (Lys12, Lys41, andArg78) (22, 23). It is thus tentative
to hypothesize that also for p17, the main contribution to hep-
arin interaction derives from linear basic motifs, with a minor
role played by tridimensional structures. At variance, p17
unfolding hampers its binding to CXCR1 indicating that, for
this interaction, the N-terminal basic domain (along with addi-
tional structures) need to be presented to the chemokine recep-
tor in a proper tridimensional conformation.
In effect, p17 possess two linear basic motifs: the first in its
N-terminal globular part, the second in its partially unfolded
C-terminal tail, a region readily accessible to interactions both
in the monomeric and trimeric forms of p17. Nevertheless,
neutralization or deletion of the C-terminal basic motif does
not abolish the heparin-binding capacity of p17, although neu-
tralization of the N-terminal basic motif causes a complete loss
of p17 heparin-binding capacity, indicating that thismotif is the
main responsible for the interaction of p17 with the GAG.
Interestingly, independent studies have revealed that theN-ter-
minal but not the C-terminal basic motif of p17 is required to
other p17 biological activities, such as HIV particle production
and infectivity (3, 63).
As alreadymentioned, however, heat denaturation induces a
3-fold decrease of the p17 affinity for heparin, suggesting that,
in addition to the linear N-terminal basic motif, additional
points of interaction with the GAG may originate after p17
folding. In effect, molecular docking studies predicted that the
binding of heparin to p17 is characterized by an extensive
hydrogen-bonding network of interactions occurring mainly
between the negatively charged groups of heparin and the con-
tiguous lysines of theN-terminal basicmotif.However, an addi-
tional contribution to the interaction seems to be given by an
arginine localized at position 39 in the second -helix that is
distant in the sequence but close to the stretch of lysines in the
folded structure. Thus, heat denaturation could unfold the 
helix, distancing Arg39 from the N-terminal basic motif, reduc-
ing the width of the zone of interaction and thus the affinity of
the binding. Further site-directed mutagenesis experiments
and SPR analyses are required to formally prove this possibility.
Different biochemical features of heparin impact its capacity
to bind p17. (i) Sulfate groups, rather than the carbonic back-
bone of heparin, mediate its interaction with p17. Indeed,
unsulfated K5 polysaccharide shows a very limited p17 binding
capacity. Also, among the GAGs tested, a correlation exists
between their sulfation degree and their capacity to inhibit p17/
heparin interaction. (ii) Other than the sulfation degree, also
the specific disposition of the sulfate groups along the heparin
chain impacts its p17-binding capacity: in effect, the p17 antag-
onist capacity of K5NS is higher than that of K5OSL despite its
lower SO3/COOH (1.0 and 1.41, respectively, Table 1). Also,
K5OSH and K5OSL exert a similar p17 antagonist activity
despite the fact that the former is endowed with a SO3COOH
ratio that is three times higher that the latter (3.77 and 1.41,
respectively (Table 1 and Fig. 4B). Thus,N-sulfate groups seem
tobe particularly important for the interaction ofK5derivatives
with p17, whereas an increase in O-sulfation does not contrib-
ute further to their p17-binding capacity. Accordingly, by plot-
ting the percent of sulfation of the different positions in the
GAGs (see Table 1) versus their capacity to inhibit the binding
of p17 to immobilized heparin, a moderate correlation (r 
0.70) can be calculated only for the Glc-NSO3 position (data
not shown). (iii) Epimerization of the GAGs decreases their
p17-binding capacity. Indeed, non-epimerized K5NS is a stron-
ger p17 binder than epimerized 6-O- and 2-O-desulfated hepa-
rins, despite these two latter GAGs retain N-sulfation and a
higher sulfation degree (SO3/COOH 1.0 for K5NS and to 1.5
for the two desulfated heparins, see Table 1). (iv) The p17-
binding capacity of heparin depends on the length of its saccha-
ridic chain. Indeed, size-defined heparin oligosaccharides, all
endowed with a similar degree and disposition of sulfate
groups, compete with immobilized heparin for the binding to
p17with potencies that increase logarithmically with the length
of their saccharidic chain. Actually, in the competition binding
assay, the hexa- and tetra-, but not the disaccharide prevents
p17 binding to immobilized heparin. However, in a direct bind-
ing assay with p17 immobilized to the sensorchip, we were able
to demonstrate that also the disaccharide binds the protein
(data not shown), indicating that its lack of effect in the com-
petition assay is due to its low inhibitory potency and the dilu-
tion of the sample available. In conclusion, the results from the
binding assays support the data from computational modeling
that predict that also very short heparin sequences can bind to
p17.
According to the results of the molecular docking models, a
heparin hexasaccharide accommodates a single p17 basicmotif
(Fig. 1). However, docking simulations of the hexasaccharide
against the trimeric p17 predict a length of 26.5 Å of the
N-terminal binding site and a distance between two binding
sites of23 Å, suggesting that a heparin chain should be com-
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posed of at least 18monosaccharides to interact simultaneously
with more than one heparin binding pockets favoring cooper-
ative p17 bindings and its oligomerization, as already demon-
strated for HIV-1 Tat and other chemokines (25, 64). In effect,
we observed that the p17 antagonist capacity of heparin oligo-
saccharides increases logarithmically with their length (Fig. 4B)
and that full-length heparin effectively induces p17 oligomeri-
zation.3 Further computational studies with longer heparin
chains should be needed to appropriately characterize the
interaction of heparin with the trimeric p17 complex.
p17 binds heparin with an affinity (Kd 190 nM) that is sim-
ilar to that of gp120 (Kd  200–600 nM) and only three times
lower than that of Tat (Kd 30–60 nM), twoHIV proteins that
exploit HSPGs to mediate important biological effects (see
Introduction). On the other hand, p17 binds to HSPGs on leu-
kocytes, and although no formal demonstration has been pro-
vided, this interaction has been tentatively associated to the
modulation of inflammatory cytokines expression (14). Even if
the possibility that p17-HSPGs interaction directly induces
somebiological activity in the cell cannot be ruled out, it is likely
that HSPGs may instead act as typical co-receptors, which, by
binding p17, cause its conformational modifications/oligomer-
ization that, in turn, ameliorate its binding to signaling recep-
tors such as CXCR1. Relevant to this point, SPR analysis
revealed that p17 binds both CXCR1 and heparin with Kd val-
ues that are significantly higher that the concentrations
required to induce leukocyte migration (11), suggesting that, in
vivo, the “productive” interaction of p17 with cells consists of
the formation of a p17-HSPG-CXCR1 ternary complex, in
which the affinity of the interactions is increased, as already
demonstrated for other heparin-binding cytokines (65). This
possibility is also sustained by the observation that in the trim-
eric form of p17 the N-terminal basic motif remains exposed
onto the protein surface (34), readily accessible to receptors for
multiple interactions. Further experiments are required to clar-
ify the complex relationship existing between p17, HSPGs and
chemochine receptors at the surface of target cells.
The involvement of p17 N-terminal basic motif in the bind-
ing to both heparin and CXCR1 is not surprising. Indeed, the
basicmotif of Tat is involved in the binding toHSPGs, integrins
andVEGFR2 (61). Interestingly, selectedK5derivatives prevent
Tat interaction with all these receptors, inhibiting the conse-
quent biological activities (55). Here, we have shown that
K5NOSH prevents the binding of p17 to both HSPGs and
CXCR1, inhibiting p17-drivenmonocyte chemotaxis. Thus, the
basicmotif of p17 (aswell as those of other viral proteins) can be
considered as nodal motifs implicated in multiple interactions,
thus emerging as preferential aim for the development of mul-
titarget drugs interfering with different receptors (18). Finally,
it is also worth noting that K5 derivatives are able to interfere
with other HIV proteins (Tat and gp120, see above), suggesting
the possibility to use K5 derivatives as template for the devel-
opment of drugs endowed with an interesting anti-HIV multi-
target action, directed against both different receptors of a
given HIV protein and against different HIV proteins (18).
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